Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 6, 2014, Pages 578-585

  Charytan, David ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular; End stage renal disease; Left ventricular hypertrophy; Sudden cardiovascular death

Indexed keywords

ANGIOTENSIN;

ANEMIA; DISEASE COURSE; END STAGE RENAL DISEASE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUDDEN CARDIAC DEATH; COMPLICATION; DEATH, SUDDEN, CARDIAC; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MORTALITY; PROGNOSIS; RISK ASSESSMENT;

DEATH, SUDDEN, CARDIAC; DISEASE PROGRESSION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84927586546     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000067     Document Type: Review

References (75)

1. U.S. Renal Data System. USRDS 2013 Annual Data Report: atlas of endstage renal disease in the United States; 2013.
2. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192.
3. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248.
4. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
5. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62:1524-1538.
6. Jacobi J, Porst M, Cordasic N, et al. Subtotal nephrectomy impairs ischemiainduced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 2006; 69:2013-2021.
7. Amann K, Hofstetter J, Campean V, et al. Nonhypotensive dose of betaadrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. Virchows Arch 2006; 449:207-214.
8. Amann K, Neimeier KA, Schwarz U, et al. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis 1997; 30:382-388.
9. Amann K, Wiest G, Zimmer G, et al. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 1992; 42:1079-1085.
10. Dikow R, Kihm LP, Zeier M, et al. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004; 15:1530-1536.
11. Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int Suppl 2003; S80-S83.
12. Dikow R, Schmidt U, Kihm LP, et al. Uremia aggravates left ventricular remodeling after myocardial infarction. Am J Nephrol 2010; 32:13-22.
13. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9:1018-1022.
14. Chade AR, Brosh D, Higano ST, et al. Mild renal insufficiency is associated with reduced coronary flow in patients with nonobstructive coronary artery disease. Kidney Int 2006; 69:266-271.
15. Koivuviita N, Tertti R, Jarvisalo M, et al. Increased basal myocardial perfusion in patients with chronic kidney disease without symptomatic coronary artery disease. Nephrol Dial Transplant 2009; 24:2773-2779.
16. Tok D, Gullu H, Erdogan D, et al. Impaired coronary flow reserve in hemodialysis patients: a transthoracic Doppler echocardiographic study. Nephron Clin Pract 2005; 101:c200-c206.
17. Charytan DM, Shelbert HR, Di Carli MF. Coronary microvascular function in early chronic kidney disease. Circ Cardiovasc Imaging 2011; 3:663-671.
18. Meier P, Gloekler S, Zbinden R, et al. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 2007; 116:975-983.
19. Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327:1825-1831.
20. Sezer M, Ozcan M, Okcular I, et al. A potential evidence to explain the reason behind the devastating prognosis of coronary artery disease in uraemic patients: renal insufficiency is associated with poor coronary collateral vessel development. Int J Cardiol 2007; 115:366-372.
21. Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69:1839-1845.
22. Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2015; 5:805-813.
23. de Almeida EA, de Oliveira EI, Lopes JA, et al. Diastolic function in several stages of chronic kidney disease in patients with autosomal dominant polycystic kidney disease: a tissue Doppler imaging study. Kidney Blood Press Res 2007; 30:234-239.
24. Afshinnia F, Spitalewitz S, Chou SY, et al. Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure. Am J Kidney Dis 2007; 49:227-236.
25. Edwards NC, Ferro CJ, Townend JN, Steeds RP. Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart 2008; 94:1038-1043.
26. Masugata H, Senda S, Goda F, et al. Echocardiographic assessment of the cardio-renal connection: is left ventricular hypertrophy or diastolic function more closely correlated with estimated glomerular filtration rate in patients with cardiovascular risk factors? Clin Exp Hypertens 2010; 32:113-120.
27. Bruch C, Rothenburger M, Gotzmann M, et al. Chronic kidney disease in patients with chronic heart failure-impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol 2007; 118:375-380.
28. Wang AY, Wang M, Lam CW, et al. Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Hypertension 2008; 52:107-114.
29. Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial 2008; 21:308-318.
30. Nitta K, Akiba T, Uchida K, et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27:47-52.
31. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009; 4 (Suppl 1):S79-S91.
32. Naito Y, Tsujino T, Matsumoto M, et al. Adaptive response of the heart to longterm anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009; 296:H585-H593.
33. MacRae JM. Vascular access and cardiac disease: is there a relationship? Curr Opin Nephrol Hypertens 2006; 15:577-582.
34. Ozkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998; 13:1489-1493.
35. Yamakawa H, Imamura T, Matsuo T, et al. Diastolic wall stress and ANG II in cardiac hypertrophy and gene expression induced by volume overload. Am J Physiol Heart Circ Physiol 2000; 279:H2939-H2946.
36. Paulis L, Matuskova J, Adamcova M, et al. Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. Acta Physiol (Oxf) 2008; 194:45-55.
37. Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999; 12:867-873.
38. Steigerwalt S, Zafar A, Mesiha N, et al. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007; 27:159-163.
39. Cannella G, Paoletti E, Delfino R, et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30:659-664.
40. Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207:186-190.
41. Mizobuchi M, Nakamura H, Tokumoto M, et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121:188-192.
42. Fujii H, Kim JI, Abe T, et al. Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. Intern Med 2007; 46:1507-1512.
43. van Ballegooijen AJ, Visser M, Kestenbaum B, et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol 2013; 111:418-424.
44. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
45. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545-2552.
46. Kazakov A, Muller P, Jagoda P, et al. Endothelial nitric oxide synthase of the bone marrow regulates myocardial hypertrophy, fibrosis, and angiogenesis. Cardiovasc Res 2012; 93:397-405.
47. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62:339-345.
48. Kennedy DJ, Vetteth S, Periyasamy SM, et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006; 47:488-495.
49. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009; 75:800-808.
50. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47:186-192.
51. Takeda A, Toda T, Iwamoto H, et al. Long-term evolution and changing associations of left ventricular hypertrophy after starting hemodialysis. Nephron Clin Pract 2008; 110:c126-c132.
52. Bansal N, Keane M, Delafontaine P, et al. A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study. Clin J Am Soc Nephrol 2013; 8:355-362.
53. Hayashi T, Kimura T, Yasuda K, et al. Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the predialysis use of erythropoiesis-stimulating agents. Clin Exp Nephrol 2013; 17:294-303.
54. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 50:1009-1019.
55. Madsen LH, Ladefoged S, Corell P, et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71:548-554.
56. Dimitrijevic Z, Cvetkovic T, Stojanovic M, et al. Prevalence and risk factors of myocardial remodeling in hemodialysis patients. Ren Fail 2009; 31:662-667.
57. Virga G, Stomaci B, Munaro A, et al. Systolic and diastolic function in renal replacement therapy: a cross-sectional study. J Nephrol 2006; 19:155-160.
58. Kutlay S, Dincer I, Sengul S, et al. The long-termbehavior and predictors of left ventricular hypertrophy in hemodialysis patients. Am J Kidney Dis 2006; 47:485-492.
59. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65:1492-1498.
60. Foley RN, Parfrey PS, Kent GM, et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11:912-916.
61. Moon KH, Song IS, Yang WS, et al. Hypoalbuminemia as a risk factor for progressive left-ventricular hypertrophy in hemodialysis patients. Am J Nephrol 2000; 20:396-401.
62. Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2010; 5:805-813.
63. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36:286-290.
64. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002; 40:1202-1210.
65. Foley RN, Parfrey PS, Harnett JD, et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5:2024-2031.
66. Kim SJ, Oh HJ, Yoo DE, et al. Electrocardiographic left ventricular hypertrophy and outcome in hemodialysis patients. PLoS One 2012; 7:e35534.
67. Kessler M, Zannad F, Lehert P, et al. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the fosinopril in dialysis study. Nephrol Dial Transplant 2007; 22:3573-3579.
68. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12:2759-2767.
69. Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90:256-261.
70. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 2004; 8:320-327.
71. Matsumoto N, Ishimitsu T, Okamura A, et al. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res 2006; 29:253-260.
72. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70:1318-1324.
73. Chan CT, Greene T, Chertow GM, et al., Frequent Hemodialysis Network Trial G. Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling. Clin J Am Soc Nephrol 2013; 8:2106-2116.
74. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 2009; 4:755-762.
75. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58:1325-1335.